{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:32:51Z","timestamp":1780353171798,"version":"3.54.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiology Case Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.radcr.2024.06.034","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T22:56:19Z","timestamp":1719874579000},"page":"3959-3961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pembrolizumab-induced vasculitis demonstrated by FDG-PET\/CT"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-8450","authenticated-orcid":false,"given":"Tuan","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-101X","authenticated-orcid":false,"given":"Sophia R.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-1194","authenticated-orcid":false,"given":"Shawn X.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9392-7910","authenticated-orcid":false,"given":"Karthik M.","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin R.","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.radcr.2024.06.034_bib0001","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.radcr.2024.06.034_bib0002","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/BOR.0000000000000672","article-title":"Immune checkpoint inhibitors and vasculitis","volume":"32","author":"Boland","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.radcr.2024.06.034_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.radcr.2024.06.034_bib0004","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1212\/CPJ.0000000000000768","article-title":"Pembrolizumab-induced CNS vasculitis: neurologic adverse events due to checkpoint inhibitors","volume":"11","author":"Feng","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.radcr.2024.06.034_bib0005","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.ajoc.2021.101072","article-title":"A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.radcr.2024.06.034_bib0006","first-page":"7971169","article-title":"A case report of immune checkpoint inhibitor-induced aortitis treated with tocilizumab","volume":"2022","author":"Bloomer","year":"2022","journal-title":"Case Rep Immunol"},{"key":"10.1016\/j.radcr.2024.06.034_bib0007","doi-asserted-by":"crossref","first-page":"774170","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarr\u00e1n","year":"2022","journal-title":"Front Pharmacol"},{"issue":"March","key":"10.1016\/j.radcr.2024.06.034_bib0008","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.radcr.2024.06.034_bib0009","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.radcr.2024.06.034_bib0010","article-title":"Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy","volume":"2017","author":"Roy","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.radcr.2024.06.034_bib0011","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/RLU.0000000000003215","article-title":"Nivolumab-induced periaortitis demonstrated by FDG PET\/CT","volume":"45","author":"Hotta","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Radiology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043324005235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043324005235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:17:38Z","timestamp":1733217458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1930043324005235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1930043324005235"],"URL":"https:\/\/doi.org\/10.1016\/j.radcr.2024.06.034","relation":{},"ISSN":["1930-0433"],"issn-type":[{"value":"1930-0433","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced vasculitis demonstrated by FDG-PET\/CT","name":"articletitle","label":"Article Title"},{"value":"Radiology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radcr.2024.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of University of Washington.","name":"copyright","label":"Copyright"}]}}